Logos Capital

  • Logos
  • About
  • Team
  • Logos Analytics
    • Data Aggregation
    • Model Validation
    • Predictive Matrix
  • Investments
  • Contact
  • Investor Login

Home

_Vectors_WEB-01-03-trans

Logos, the Greek word for logic and discourse, emphasizes our philosophy of seeking empirical truth and rigorous scientific diligence across our investment endeavors.

Seeking Logos

Logos Capital is a fundamental biotechnology-focused investment partnership that combines scientific and financial expertise with in-house clinical trial analytics to identify transformative therapies in healthcare. Based in San Francisco, Logos combines expertise across medical, scientific, and statistical disciplines to expand the depth of diligence in identifying compelling investment themes and opportunities.

beakers dna image

Our Mission

Build a world-class biotechnology investment partnership, focused on generating superior long-term returns for our investors and financing innovation that will meaningfully advance the standard of care for patients

Success in drug development is contingent on more than just scientific research. Our process focuses on event tracking, clinical trial underwriting, risk management, and a culture rooted in technical diligence and continuous improvement.  We seek to holistically assess an asset from its preclinical data through commercialization potential to determine intrinsic value.

Adobe Stock-© Quality Stock Arts
inspection

Identify

We rigorously track and diligence all private and public companies in our sector, looking for best in class or first in class companies with attractive valuations.

invest

Invest

New technologies and therapeutic approaches are leading to functional cures, expanding patient access, extending life expectancy and redefining the meaning of ‘value.’ We continually screen for opportunities that are clear advances to the current treatment paradigm and standard of care.

deliver value

Deliver Value

Our mandate is to deliver best-in-class returns to our investors. To do so, we thoroughly underwrite each investment, incorporating multiple layers of risk management to ensure our rationale, our “logos”, is perpetually aligned with those supporting us.

Team

The Logos team is composed of trained experts in the field of chemistry, engineering, biology, and data science. We are committed to supporting true innovation through investing directly in companies pushing the boundaries of medical science and patient care

  • Investment

  • Operations

  • View All

Investment

Dr Arsani William

Dr. Arsani William, MD, MBA

Managing Partner, Chief Investment Officer
Dr. William serves as Managing Partner and Chief Investment Officer of Logos Capital, a global life science investment fund focused on private / public therapeutic innovation. Prior to founding Logos, Dr. William was an investment professional at Farallon Capital Management, where he helped grow the development of Farallon’s biopharma portfolio. Dr. William holds an MD from Harvard Medical School, where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University. Dr. William currently serves on the board of Design Therapeutics (NASDAQ: DSGN) and is a board observer on Odyssey Therapeutics.
Dr Arsani William,MD,MBA
Managing Partner,
Chief Investment Officer
Dr. Graham Walmsley

Dr. Graham Walmsley, MD, PhD

General Partner, Privates
Dr. Walmsley serves as General Partner of Logos Capital and co-manages the firm’s private efforts. Prior to Logos, Dr. Walmsley was a Principal and Manager of the crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director, built and launched multiple companies (including BlueRock Therapeutics acquired by Bayer), and was head of business development for Jecure Therapeutics through its acquisition by Roche. Dr. Walmsley currently serves on the board of Akero Therapeutics (NASDAQ: AKRO), ALX Oncology (NASDAQ: ALXO), and Olema Pharmaceuticals (NASDAQ: OLMA). Dr. Walmsley has authored more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.
Dr. Graham Walmsley, MD, PhD
General Partner,
Privates
Ed Zhong

Dr. Ed Zhong, PhD

Partner, Analytics
Dr. Zhong serves as Head of Logos Analytics and the firm’s Data Science effort. Prior to Logos, Dr. Zhong was the founding data scientist at Farallon Capital Management, where he helped lead the development of clinical trial models, analysis of large datasets, and antitrust models for M&A situations. Ed holds a BA in Economics from Harvard University and a PhD in Economics from the University of Madison.
Dr. Ed Zhong, PhD
Partner,
Analytics

Operations

John Rogers, CPA

Chief Operating Officer
John serves as the Chief Operating Officer of Logos Capital and has more than twenty years of experience serving in various executive capacities in the alternative investments industry. Prior to joining Logos, John was a Partner, Chief Financial Officer and founding member of Palestra Capital, which he joined in 2011 helping grow the firm from launch to ~$4.5bn. Prior to Palestra, John was the Chief Operating Officer and Chief Financial Officer at Greenheart Capital. John also held similar roles at Obrem Capital and Stadia Capital where he implemented and operated the non-investment operations of each firm. John graduated with a B.S. from the State University of New York at Oneonta and is a Certified Public Accountant (non-practicing).
John Rogers, CPA
Chief Operating Officer

Virginia Yee

Chief Financial Officer & Chief Compliance Officer
Virginia serves as Chief Financial Officer and Chief Compliance Officer of Logos Capital. Prior to Logos, Virginia was COO and CCO of Pelorus Jack Capital. Virginia was a Founding Member and COO at 7x7 Asset Management from 2005 to 2014. Prior to 2010, she was also CCO and responsible for managing financial and tax reporting for the funds and overseeing investor relations. Virginia has over twenty years of operating, financial and compliance experience and has held various operational positions throughout her career at Stratix Asset Management, Seasons Capital Management and Robertson Stephens & Co. Virginia graduated with a B.A. in Economics from University of California, Berkeley.
Virginia Yee
Chief Financial Officer &
Chief Compliance Officer

Riki Harada

Controller
Riki serves as the Controller for Logos Capital. Prior to Logos, Riki was the Operations and Compliance Manager at Banyan Alpha Investments. Prior to that, he was the Controller and Director of Operations at Sensato Investors. Riki has over 16 years of industry experience with a B.A. from University of California, Berkeley.
Riki Harada
Controller

Bonny Chen

Executive Assistant and Office Manager
Bonny serves as the Executive Assistant and Office Manager for Logos Capital. Previously, she was the Executive Assistant to the Partner, CFO and COO and the Director of Legal Affairs and supported the Operations team at a venture capital firm, 137 Ventures. Prior to 137 Ventures, she also supported the Asset Management, Investor Relations, and Office Operations at a real estate investment trust, Carmel Partners. Bonny has over 10 years of experience as an Executive Assistant and Operations Administrator with a B.A. from University of California, Riverside.
Bonny Chen
Executive Assistant
OfficeManager

View All

Dr Arsani William

Dr. Arsani William, MD, MBA

Managing Partner, Chief Investment Officer
Dr. William serves as Managing Partner and Chief Investment Officer of Logos Capital, a global life science investment fund focused on private / public therapeutic innovation. Prior to founding Logos, Dr. William was an investment professional at Farallon Capital Management, where he helped grow the development of Farallon’s biopharma portfolio. Dr. William holds an MD from Harvard Medical School, where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University. Dr. William currently serves on the board of Design Therapeutics (NASDAQ: DSGN) and is a board observer on Odyssey Therapeutics.
Dr Arsani William,MD
Managing Partner,
Chief Investment Officer
Dr. Graham Walmsley

Dr. Graham Walmsley, MD, PhD

General Partner, Privates
Dr. Walmsley serves as General Partner of Logos Capital and co-manages the firm’s private efforts. Prior to Logos, Dr. Walmsley was a Principal and Manager of the crossover fund at Versant Ventures where he invested in biotechnology companies across multiple funds totaling over $1.5 billion in AUM. While at Versant, Dr. Walmsley served as a board director, built and launched multiple companies (including BlueRock Therapeutics acquired by Bayer), and was head of business development for Jecure Therapeutics through its acquisition by Roche. Dr. Walmsley currently serves on the board of Akero Therapeutics (NASDAQ: AKRO), ALX Oncology (NASDAQ: ALXO), and Olema Pharmaceuticals (NASDAQ: OLMA). Dr. Walmsley has authored more than 60 scientific publications and holds an MD and PhD from Stanford University School of Medicine.
Dr. Graham Walmsley, MD, PhD
General Partner,
Privates
Ed Zhong

Dr. Ed Zhong, PhD

Partner, Analytics
Dr. Zhong serves as Head of Logos Analytics and the firm’s Data Science effort. Prior to Logos, Dr. Zhong was the founding data scientist at Farallon Capital Management, where he helped lead the development of clinical trial models, analysis of large datasets, and antitrust models for M&A situations. Ed holds a BA in Economics from Harvard University and a PhD in Economics from the University of Madison.
Dr. Ed Zhong, PhD
Partner,
Analytics

John Rogers, CPA

Chief Operating Officer
John serves as the Chief Operating Officer of Logos Capital and has more than twenty years of experience serving in various executive capacities in the alternative investments industry. Prior to joining Logos, John was a Partner, Chief Financial Officer and founding member of Palestra Capital, which he joined in 2011 helping grow the firm from launch to ~$4.5bn. Prior to Palestra, John was the Chief Operating Officer and Chief Financial Officer at Greenheart Capital. John also held similar roles at Obrem Capital and Stadia Capital where he implemented and operated the non-investment operations of each firm. John graduated with a B.S. from the State University of New York at Oneonta and is a Certified Public Accountant (non-practicing).
John Rogers, CPA
Chief Operating Officer

Virginia Yee

Chief Financial Officer & Chief Compliance Officer
Virginia serves as Chief Financial Officer and Chief Compliance Officer of Logos Capital. Prior to Logos, Virginia was COO and CCO of Pelorus Jack Capital. Virginia was a Founding Member and COO at 7x7 Asset Management from 2005 to 2014. Prior to 2010, she was also CCO and responsible for managing financial and tax reporting for the funds and overseeing investor relations. Virginia has over twenty years of operating, financial and compliance experience and has held various operational positions throughout her career at Stratix Asset Management, Seasons Capital Management and Robertson Stephens & Co. Virginia graduated with a B.A. in Economics from University of California, Berkeley.
Virginia Yee
Chief Financial Officer &
Chief Compliance Officer

Riki Harada

Controller
Riki serves as the Controller for Logos Capital. Prior to Logos, Riki was the Operations and Compliance Manager at Banyan Alpha Investments. Prior to that, he was the Controller and Director of Operations at Sensato Investors. Riki has over 16 years of industry experience with a B.A. from University of California, Berkeley.
Riki Harada
Controller

Riki Harada

Controller
Riki serves as the Controller for Logos Capital. Prior to Logos, Riki was the Operations and Compliance Manager at Banyan Alpha Investments. Prior to that, he was the Controller and Director of Operations at Sensato Investors. Riki has over 16 years of industry experience with a B.A. from University of California, Berkeley.
Riki Harada
Controller

Bonny Chen

Executive Assistant and Office Manager
Bonny serves as the Executive Assistant and Office Manager for Logos Capital. Previously, she was the Executive Assistant to the Partner, CFO and COO and the Director of Legal Affairs and supported the Operations team at a venture capital firm, 137 Ventures. Prior to 137 Ventures, she also supported the Asset Management, Investor Relations, and Office Operations at a real estate investment trust, Carmel Partners. Bonny has over 10 years of experience as an Executive Assistant and Operations Administrator with a B.A. from University of California, Riverside.
Bonny Chen
Executive Assistant
OfficeManager

Investments

PC-blue-tag

Denotes public company

bseat-gold-tag

Denotes board seat

bacquired-green-tag

Denotes acquired

858Therapeutics-Portfolio-300X300

858 THERAPEUTICS INC


Affinivax-Portfolio-img

Affinivax


Visit Site
Aigos_tag-Portfolio-300X300

Aligos Therapeutics
Aligos is developing targeted, curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B virus, non-alcoholic steatohepatitis and hepatocellular carcinoma.


Visit Site
ALX-Portfolio-300X300

ALX Oncology
ALX Oncology is a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint mechanism, which is exploited by cancer cells to evade the immune system. 


Visit Site
Annexon_tag-Portfolio-300X300

Annexon Biosciences
Annexon Biosciences is a pioneer in developing C1q inhibitors designed to treat multiple complement-medicated autoimmune and neurodegenerative diseases.


Visit Site
Athira_tag-Portfolio-300X300

Athira Pharma
Athira Pharma is a clinical stage therapeutics company developing regenerative therapies for neurological diseases such as Alzheimer's disease and Parkinson's disease.


Visit Site
Avidity-Portfolio-300X300

Avidity Biosciences
Avidity Biosciences is a privately held biotech company pioneering Antibody Oligonucleotide Conjugates (AOC™). AOCs combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapeutics to overcome barriers to the delivery of oligonucleotides and target genetic drivers of disease.


Visit Site
BDT-Portfolio-300X300

Black Diamonds Therapeutics
Black Diamond Therapeutics is a Precision Oncology Medicine Company Pioneering the Discovery of Small Molecule, Tumor-Agnostic Therapies


Visit Site
biomea-Portfolio-img_tag

Biomea Fusion


Visit Site
boundlessbio-Portfolio-300X300

Boundless BIO INC


Visit Site
C4-Therapeutics-Portfolio_tag-300X300

C4 Therapeutics
C4 Therapeutics is committed to transforming the treatment of cancer, neurological, and other important diseases with novel early stage therapies that eliminate disease-causing proteins. C4’s approach to medicine harnesses the innate machinery of the cell to attack disease and potentially bring deep and durable responses to patients.


Visit Site
centessa-Portfolio-tag

Centessa Pharmaceuticals


Visit Site
century-Portfolio-tag

Century Therapeutics


Visit Site
cogent-Portfolio-img-pub_tag

Cogent Biosciences
Cogent Biosciences is a biotechnology company developing therapies for genetically driven diseases.


Visit Site
cullinan-Portfolio-img-pu_tag

Cullinan Oncology


Visit Site
dayone-Portfolio-tag

Day One Biopharmaceuticals


Visit Site
design-Portfolio-img_tag2

Design Therapeutics


Visit Site
Dyne-Portfolio-img-pub_tag

Dyne Therapeutics
Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases.


Visit Site
edgewise-Portfolio-img_tag

Edgewise Therapeutics


Visit Site
element-Portfolio-300X300

Element Biosciences INC


Visit Site
enliven-Portfolio-img

Enliven Therapeutics


Visit Site
Flame-Portfolio-300X300

Flame Biosciences
Flame Biosciences is a clinical stage company focused on the research, development and commercialization of transformative therapies for cancer and other inflammatory conditions.


Visit Site
Gennao-Portfolio-img

Gennao Bio
Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology.


Visit Site
ghresearch-Portfolio-tag

GH Research


Visit Site
graphite-Portfolio-tag

Graphite Bio


Visit Site
iconovir-Portfolio-img

IconOVir Bio


Visit Site
ikena-Portfolio-img_tag

Ikena Oncology


Visit Site
InstilBio-Portfolio-img_tag

InstilBio
Instil Bio is a cell therapy company focused on solid tumors developing patient specific immunotherapies in oncology, allowing the patient’s own immune system to be harnessed to fight cancer.


Visit Site
interius-Portfolio-300X300

Interius


Visit Site
janux-Portfolio-tag

Janux


Visit Site
Kinnate-Portfolio-img-pub_tag

Kinnate Biopharma
Kinnate Biopharma is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities. Kinnate design and develop selective small molecules with the mission to provide the right drug to the right patient.


Visit Site
Kymera-Portfolio-img-pub_tag

Kymera Therapeutics
Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases, advancing the field of targeted protein degradation by accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins.


Visit Site
lianbio-Portfolio-img

LianBio


Visit Site
Nkarta-Portfolio-300X300

Nkarta Therapeutics
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.


Visit Site
nkt-Portfolio-300X300

Nikang Therapeutics INC


Visit Site
nuvalent-Portfolio-300X300

Nuvalent INC


Visit Site
Olema-Portfolio-img-two_tag

Olema Pharmaceuticals
Olema is a preclinical biotechnology company developing new drugs for the treatment and prevention of estrogen receptor (ER) positive breast cancer. At Olema we leverage the exquisite knowledge of the molecular action of the ER to design compounds that are superior to both the current drugs and those in development.


Visit Site
Passage-Portfolio-300X300

Passage Bio
Passage Bio is a genetic medicines company developing transformative therapies for the treatment of rare monogenic central nervous system diseases


Visit Site
Pliant-Portfolio-300X300

Pliant Therapeutics
Pliant Therapeutics is a clinical stage biopharmaceutical company unraveling and targeting the key biological pathways driving fibrosis.


Visit Site
quantath-Portfolio-img

Quanta Therapeutics
No Website


rain-Portfolio-img_tag

Rain Therapeutics
Rain Therapeutics Inc. is a privately-held biotechnology company developing targeted therapies for patients with cancer. 


Visit Site
rayzebio-Portfolio-img

Rayze Bio


Visit Site
repare-Portfolio-300X300

Repare Therapeutics
Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumor cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s platform combines a proprietary, high throughput, CRISPR‐enabled gene editing target discovery method with high‐resolution protein crystallography, computational biology and clinical informatics.


Visit Site
scorpion-Portfolio-img

Scorpion Therapeutics


Visit Site
shoreline-Portfolio-img

Shoreline Biosciences


Visit Site
somalogic-Portfolio-img

SomaLogic


Visit Site
talaris-Portfolio-tag

Talaris Therapeutics
Talaris is developing a single-dose cell therapy that seeks to produce durable immune tolerance to both an individual’s own tissues as well as donated organs from another individual.


Visit Site
velosbio-Portfolio-img-acq-tag

VelosBio
VelosBio is a clinical-stage biopharmaceutical company committed to developing novel, first-in-class, ROR1-directed therapeutics to transform the lives of patients with cancer.


Visit Site
ventyx-Portfolio-300X300

Ventyx Biosciences


Visit Site
verve-Portfolio-tag

Verve Therapeutics


Visit Site
visen-Portfolio-img

Visen Pharmaceuticals
VISEN Pharmaceuticals is committed to the treatment of endocrine-related diseases, introducing the world's leading treatment methods and drugs into the China market, and hoping to provide more Chinese patients quick access to the world's most advanced and reliable treatment solutions. In 2018, VISEN Pharmaceuticals was formed by Ascendis Pharma A/S (Nasdaq: ASND) and an investor syndicate led by Vivo Capital (along with participation by Sofinnova Investments), to develop and commercialize endocrinology therapies in Greater China, which includes mainland China, Hong Kong, Macau, and Taiwan.

vividion-Portfolio-tag2

Vividion Therapeutics


Visit Site
willow-one-Portfolio-300X300

Willow


Visit Site

Contact Us

  • Logos Capital
    1 Letterman Drive
    Building C, Suite C3-350
    San Francisco, CA 94129

  • +1 (415) 801-4660

  • contact@logoscapital.com

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Logos Global Management LP (“Logos Capital”). Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Logos Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Logos Capital were prepared based upon information, believed to be reliable, available to it at the time such views were written. Logos Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Logos Capital.

© 2023 Logos Capital